Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients

Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients

Dupilumab was the first biological medication licensed to treat atopic dermatitis (AD), and it has shown remarkable effectiveness and safety in the treatment of moderate-to-severe atopic dermatitis. There are limited drug-related adverse events associated with dupilumab in atopic dermatitis (AD) tre...

Full description

Bibliographic Details
Main Authors: Min Chen, Kai Gao, Kamran Ali, Jinpeng Shan, YunMi Qiu, Tianci Xie, Yiling Yu, Liming Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Medicine
Subjects:
Staphylococcus aureus infection
adverse event
atopic dermatitis
dupilumab adverse reactions
drug reaction
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1027589/full

Similar Items

Similar Items